Mendelian Randomization Reveals the Role of HMGCR in Pulmonary Arterial Hypertension Treatment, Independent of LDL Cholesterol Concentration
Shixun Wu,Jie Pu,Zhiguo Tang,Wei Zhang,Fangxia Hou,Na Wei,Qianwei Cui,Fuqiang Liu,Junkui Wang,Ying Lv,Tao Wei,Wu,S.,Pu,J.,Tang,Z.,Zhang,W.,Hou,F.,Wei,N.,Cui,Q.,Liu,F.,Wang,J.,Lv,Y.,Wei,T.
DOI: https://doi.org/10.1101/2023.10.02.23295606
2023-10-05
MedRxiv
Abstract:Introduction: Specific lipid-reducing therapeutics, including statins, are known for mitigating cardiovascular diseases due to their comprehensive benefits including anti-inflammatory properties, antioxidative stress response, and enhancement of endothelial function. The objective of our study was to determine the causative impact of lipid-reducing agents (HMGCR inhibitors, PCSK9 inhibitors, and NPC1L1 inhibitor) on the outcomes of pulmonary hypertension via a two-sample Mendelian randomization (MR) analysis. Methods: Two types of genetic tools were employed to estimate the exposure to lipid-lowering drugs, comprising expression quantitative trait loci of the drug's target genes and genetic variations close to or within the target genes related to low-density lipoprotein (LDL cholesterol derived from a genome-wide association study). We utilized summary-data-based MR (SMR) and inverse-variance-weighted MR (IVWMR) methodologies for estimating effect sizes. Results: SMR analysis indicated that elevated HMGCR expression correlates with increased pulmonary hypertension risk ({beta}=-0.964, se=0.276). Yet, no evident causative link between HMGCR-regulated LDL cholesterol and COVID-19 hospitalization was observed in the IVW-MR analysis ({beta} = -0.21, se= 0.17). Conclusions: Our Mendelian randomization investigation unveiled a possible positive impact of lipid-lowering therapeutics on the prognosis of pulmonary hypertension. Importantly, no causal relation was established between LDL cholesterol and pulmonary hypertension.